Change of Broker

RNS Number : 6139X
Sareum Holdings PLC
26 June 2008
 



For immediate release

26 June 2007



SAREUM HOLDINGS PLC

("Sareum" or the "Company")


Change of Broker


Sareum Holdings plc (Sareum) (AIM: SAR), the specialist structure-based drug discovery business, announces the appointment of Hybridan as sole broker to the Company with immediate effect. 



For further information: 


Sareum Holdings

01223 497700

Tim Mitchell, Chief Executive Officer




Hybridan

0203 159 5085

Claire Noyce / Ravi Lockyer




Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett / Colin Aaronson




Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 



Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered in CambridgeUK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer. Sareum's unique approach aims to halve the time it takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the three-dimensional structure of the proteins that cause disease. Once the structure is known, potential drugs are designed to 'lock-in' to the protein with the aim of reversing or arresting a disease's progression. Knowledge of the structure of the potential drugs and how they 'lock-in' to their target protein assists greatly in the development of high-quality drug candidates. Determining structure is a complex task and requires leading-edge equipment and experienced staff. Sareum's approach to structure determination utilises its proprietary protein expression platform in order to produce multiple recombinant proteins that accelerate structure determination using x-ray crystallography. 

Once the structure is determined, the Company's innovative fragment screening platform is used to identify novel chemical templates designed to interact with the target protein. Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger pharmaceutical companies at the pre-clinical or early clinical trials stage. This is funded by provision of its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR. For further information, please visit www.sareum.co.uk



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPFQLFLVQBLBBZ
UK 100

Latest directors dealings